GRAIL, Inc. (NASDAQ:GRAL) Stock Has Consensus Price Target of $93.60 According to Analysts

GRAIL, Inc. (NASDAQ:GRAL) has been assigned an average recommendation of “Hold” from the twelve analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $102.70.

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of GRAIL in a report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 target price on the stock. Mizuho boosted their price target on shares of GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, September 25th. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a research note on Thursday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. Finally, Robert W. Baird lifted their target price on shares of GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd.

GRAIL Trading Down 10.9%

Shares of GRAL opened at $137.28 on Friday. GRAIL has a 1 year low of $41.50 and a 1 year high of $166.48. The stock has a 50 day simple moving average of $88.31 and a 200-day simple moving average of $70.39. The stock has a market cap of $6.13 billion, a PE ratio of -14.08 and a beta of 2.83.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. The business had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. On average, sell-side analysts forecast that GRAIL will post -10.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Aaron Freidin sold 4,100 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $93.34, for a total transaction of $382,694.00. Following the sale, the chief financial officer owned 248,983 shares in the company, valued at approximately $23,240,073.22. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua J. Ofman sold 61,452 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $97.74, for a total value of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares of the company’s stock, valued at approximately $35,408,367.54. This trade represents a 14.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 78,452 shares of company stock valued at $7,485,691 over the last ninety days. Insiders own 1.83% of the company’s stock.

Institutional Investors Weigh In On GRAIL

A number of hedge funds have recently added to or reduced their stakes in the stock. Fifth Third Bancorp increased its holdings in shares of GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of GRAIL in the 4th quarter valued at $28,000. Geneos Wealth Management Inc. raised its position in shares of GRAIL by 160.0% during the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock worth $30,000 after acquiring an additional 360 shares during the last quarter. Allworth Financial LP bought a new stake in shares of GRAIL during the second quarter worth $35,000. Finally, Osbon Capital Management LLC acquired a new position in shares of GRAIL during the fourth quarter valued at $51,000.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.